Thymocartin - ≥95% , CAS No.85466-18-8

CAS: 85466-18-8 Cat. No.: T1041399 Formula: C₂₁H₄₀N₈O₇ Peso molecolare: 516.600

GRADE & PURITY ≥95%

Storage

Room temperature

Specifications

Specifiche e purezza

≥95%

Condizioni di conservazione di stoccaggio

Room temperature

Tipo di azione

INHIBITOR

Purezza

≥95%

Nomi e identificatori

• Sorrisi canonici: CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N
• IUPAC Name: (2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoic acid
• InChIKey: COIXXKVZEXZCLU-YXWQFLTLSA-N
• INCHI: 1S/C21H40N8O7/c1-11(2)16(20(35)36)29-19(34)14(10-15(30)31)28-18(33)13(7-3-4-8-22)27-17(32)12(23)6-5-9-26-21(24)25/h11-14,16H,3-10,22-23H2,1-2H3,(H,27,32)(H,28,33)(H,29,34)(H,30,31)(H,35,36)(H4,24,25,26)/t12-,13-,14-,16-/m0/s1
• Peso molecolare: 516.600

Taxonomic Classification

Taxonomy Tree

• Kingdom Organic compounds
  • Superclass Organic acids and derivatives
    • Classe Carboxylic acids and derivatives
      • Subclass Amino acids, peptides, and analogues
        • Level5 Peptides
          • Level6 Oligopeptides

• Kingdom: Organic compounds
• Superclass: Organic acids and derivatives
• Classe: Carboxylic acids and derivatives
• Subclass: Amino acids, peptides, and analogues
• Intermediate Tree Nodes: Peptides
• Direct Parent: Oligopeptides
• Alternative Parents: Aspartic acid and derivatives Valine and derivatives N-acyl-L-alpha-amino acids Alpha amino acid amides Methyl-branched fatty acids N-acyl amines Dicarboxylic acids and derivatives Secondary carboxylic acid amides Amino acids Guanidines Propargyl-type 1,3-dipolar organic compounds Carboximidamides Carboxylic acids Carbonyl compounds Organic oxides Monoalkylamines Hydrocarbon derivatives
• Molecular Framework: Aliphatic acyclic compounds
• Substituents: Alpha-oligopeptide - Aspartic acid or derivatives - Valine or derivatives - N-acyl-alpha-amino acid - N-acyl-alpha amino acid or derivatives - N-acyl-l-alpha-amino acid - Alpha-amino acid amide - N-substituted-alpha-amino acid - Alpha-amino acid or derivatives - Methyl-branched fatty acid - Branched fatty acid - N-acyl-amine - Fatty amide - Dicarboxylic acid or derivatives - Fatty acyl - Fatty acid - Secondary carboxylic acid amide - Amino acid - Guanidine - Carboxamide group - Amino acid or derivatives - Organic 1,3-dipolar compound - Propargyl-type 1,3-dipolar organic compound - Carboxylic acid - Carboximidamide - Organic oxide - Organic oxygen compound - Organic nitrogen compound - Carbonyl group - Hydrocarbon derivative - Amine - Primary amine - Organooxygen compound - Primary aliphatic amine - Organonitrogen compound - Aliphatic acyclic compound
• Descrizione: This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
• External Descriptors: Not available

Data sources

1. Djoumbou Feunang Y, Eisner R, Knox C, Chepelev L, Hastings J, Owen G, Fahy E, Steinbeck C, Subramanian S, Bolton E, Greiner R, and Wishart DS. ClassyFire: Automated Chemical Classification With A Comprehensive, Computable Taxonomy. Journal of Cheminformatics, 2016, 8:61.

DOI: 10.1186/s13321-016-0174-y

Proprietà chimiche e fisiche

• Peso molecolare: 516.600 g/mol
• XLogP3: -7.400
• Hydrogen Bond Donor Count: 9
• Hydrogen Bond Acceptor Count: 10
• Rotatable Bond Count: 18
• Exact Mass: 516.302 Da
• Monoisotopic Mass: 516.302 Da
• Topological Polar Surface Area: 278.000 Ų
• Heavy Atom Count: 36
• Formal Charge: 0
• Complexity: 786.000
• Isotope Atom Count: 0
• Defined Atom Stereocenter Count: 4
• Undefined Atom Stereocenter Count: 0
• Defined Bond Stereocenter Count: 0
• Undefined Bond Stereocenter Count: 0
• The total count of all stereochemical bonds: 0
• Covalently-Bonded Unit Count: 1

Application Protocols

Item-specific, validated application protocols (e.g., recommended concentrations, incubation times, positive controls) are not provided in the Product Data for Thymocartin.

• General guidance for peptide use in assays:
  • Prepare a fresh stock solution at a known concentration (verify by UV, AAA, or gravimetry), filter sterilize if needed (0.22 μm), and store aliquots.
  • Establish a concentration–response curve spanning at least 6–8 half-log dilutions to characterize activity and potential cytotoxicity in cell-based assays.
  • Include appropriate controls (vehicle, scrambled sequence or unrelated peptide control, and orthogonal readouts if feasible).
  • Confirm stability of working solutions by LC-MS/HPLC over the assay timeframe.

For assay-specific, item-tailored protocols, please consult the CoA/Spec Sheet or literature associated with the precise sequence/structure.

Biological Roles

• Item-specific biological function: Not specified for this item; refer to primary literature and the CoA/Spec Sheet for any sequence or activity notes.

• General context for thymus-derived peptides (literature, no clinical claims):

  • Short peptides originating from or inspired by thymic hormones have been used as research tools to interrogate immune signaling pathways, T-cell development markers, and cytokine-regulated gene expression in vitro.
  • Such peptides can exhibit sequence-dependent interactions with receptors or intracellular targets, often showing pH- and ionic-strength-dependent binding.
  • In biochemical studies, these peptides may be employed to probe protein–protein interfaces, examine phosphorylation cascades, or modulate transcriptional responses in cell lines, strictly within research settings.

• Assay considerations:

  • Validate concentration–response behavior and potential off-target effects using appropriate negative controls and orthogonal readouts (e.g., reporter assays vs. phospho-protein ELISAs).
  • Confirm integrity of the peptide under experimental conditions by LC-MS to rule out degradation-driven artifacts.

Note: No medical, diagnostic, or therapeutic use is implied. The Product Data lists this item for research use only.

Buffer Applications

Thymocartin is a discrete compound and is not used as a buffering agent. Therefore, standard buffer system design (e.g., phosphate, HEPES, acetate) does not apply to this product directly.

• If preparing assay solutions containing this compound, select a buffer appropriate to your biology (e.g., PBS, HEPES, MOPS) and confirm peptide stability and solubility at the chosen pH and ionic strength (general guidance).
• For detailed, item-specific pKa or isoelectric point that would guide buffer selection, refer to the CoA/Spec Sheet or determine experimentally.

Green Alternatives

As a discrete research compound (likely peptidic), Thymocartin is not a process solvent or bulk reagent where green-replacement frameworks are typically applied. However, greener practices can be incorporated in its handling and analysis.

• Greener handling choices (general):

  • Prefer aqueous buffers over high percentages of organic cosolvents whenever compatible with solubility and assay requirements.
  • For HPLC, use water–ethanol or water–MeCN with minimized solvent volumes; consider supercritical CO2 for certain peptide purifications if appropriate equipment is available.
  • Reduce waste by preparing small-scale stock solutions and employing micro-scale assays (96–384 well formats).

• Comparison of common co-solvents (general):

  • DMSO: excellent peptidic solubilizer; low volatility; persistent in waste streams—minimize volume.
  • Ethanol: greener profile, but can denature proteins and alter cell assays at modest % v/v.
  • Acetonitrile: common in LC; moderate toxicity; recyclable in closed-loop systems.

• Stability to consider: Avoid conditions that accelerate degradation (strong base, oxidants), thereby reducing the need for re-preparation and minimizing resource use.

Item-specific green alternatives do not apply because no synthetic or processing role is defined for this compound in the Product Data.

Pharmaceutical Uses

No pharmaceutical or clinical use is claimed or supported for this product. It is supplied strictly for research use only, as indicated in the Product Data.

• Formulation context in research (general):
  • For in vitro work, peptides are commonly formulated as sterile, filtered aqueous stocks (often with minimal DMSO if required for solubility) and stored in aliquots to avoid freeze–thaw.
  • For ex vivo studies, isotonic buffers (e.g., PBS) are typically used; verify compatibility with your biological system.

Any references to pharmacopeial standards, GMP, or clinical formulation are not applicable to this catalog item unless explicitly stated on the CoA/Spec Sheet (not specified here).

Physical Properties

• Appearance (Product Data): Not specified for this item; refer to CoA/Spec Sheet.

• Melting point, boiling point, density, refractive index (item-specific): Not specified for this item; refer to CoA/Spec Sheet.

• Solubility (item-specific): Not specified for this item; refer to CoA/Spec Sheet.

• General/literature guidance for short peptides and peptidomimetics

  • Physical state: typically solid powders or lyophilized cakes.
  • Solubility: many short peptides dissolve in water, dilute acids (e.g., 0.1% TFA, dilute HCl), buffers (pH-dependent), or polar aprotics (DMSO) when hydrophobic residues are present. Final working stocks are often prepared in aqueous buffer after initial dissolution in a small volume of DMSO if necessary.
  • pKa values: depend on ionizable side chains and termini (e.g., α-COOH ~2–3; α-NH3+ ~8–9; Lys/Arg basic; Asp/Glu acidic), influencing net charge and solubility (literature, general peptide chemistry).
  • LogP: not meaningful for ionic, peptide-like analytes; distribution depends strongly on pH and sequence composition.
  • Hygroscopicity: lyophilized peptides can be moderately hygroscopic, especially with multiple basic residues.

Note: Where precise numerical specifications are needed for QC, method development, or formulation, consult the item’s CoA/Spec Sheet.

Quality and Grades

• Item-specific grade/purity: Not specified for this item; refer to CoA/Spec Sheet.

• How to interpret peptide quality metrics (general guidance):

  • Purity (HPLC area %): Common specifications are ≥95%, ≥98%, or crude. Higher purity reduces assay background and variability in biochemical screens.
  • Identity: Typically verified by high-resolution MS and, when needed, amino-acid analysis or sequence confirmation. NMR may be of limited diagnostic value for longer peptides.
  • Residual solvents/salts: Peptides produced by solid-phase synthesis may contain TFA counterions or residual reagents; salt content can influence solubility and pH in assays.
  • Water/ash/metals: Where relevant, these are reported on a CoA. For this item, specific limits are not provided here.
  • Stabilizers: Not specified for this item; refer to CoA/Spec Sheet.

• What this means for your work: If you require a particular counterion form (e.g., acetate vs TFA), peptide mapping data, or low-UV impurity profile for analytical applications, please request the lot-specific CoA/Spec Sheet prior to method development.

Reaction and Applications

This product is supplied for research screening rather than for use as a stoichiometric reagent or bulk solvent.

• Biochemical/assay applications (general for small peptides):

  • Employed as reference standards, probe ligands, or positive controls in receptor-binding, enzymatic, or cell-based signaling assays, depending on the peptide’s biology. For Thymocartin specifically, application context is not provided here; consult primary literature for assay design.
  • Useful in structure–activity relationship (SAR) panels, sequence substitution studies, and as a benchmark in peptide optimization projects.

• Analytical applications: Can serve as a system suitability standard for LC-MS method development targeted to peptide detection (retention, ionization behavior), subject to availability of identity/purity data on the CoA.

• Not typically applicable: It is not generally used in classic synthetic reactions (e.g., cross-couplings, Grignards). If chemical modification is intended (e.g., labeling), employ peptide-conjugation protocols (NHS esters, maleimide–thiol, click chemistry) with attention to side-chain selectivity.

• Practical tips:

  • Prepare fresh working solutions; avoid repeated freeze–thaw cycles.
  • Validate stability under assay conditions (pH, temperature, protease exposure) using HPLC or LC-MS.
  • Where sequence is known, consider protease inhibitors or sequence modifications to enhance stability (general guidance).

Reaction Conditions

Classical organic reaction condition guidance is not directly applicable to this item because it is supplied as a discrete research compound, not as a reagent or solvent.

• General conditions for peptide handling/modification (literature guidance):
  • Conjugations (e.g., NHS-ester to primary amines): typically performed in aqueous buffer (pH 7.5–8.5) at 4–25°C for 0.5–2 h; avoid excess base to limit hydrolysis.
  • Maleimide–thiol coupling: pH 6.5–7.5, 4–25°C, minutes to 1 h; exclude oxidants to preserve thiols.
  • Copper-catalyzed azide–alkyne cycloaddition (CuAAC): aqueous/tert-BuOH mixtures, catalytic Cu(I) (generated in situ), RT; include chelators or copper-scavenging resins post-reaction for biological use.
  • Purification: RP-HPLC (C18), gradients of water–acetonitrile with 0.05–0.1% TFA or alternative modifiers (formic acid for MS compatibility).

These are general peptide-chemistry conditions and may not apply if Thymocartin lacks the requisite functional groups. Confirm the sequence/functional handles from the CoA/Spec Sheet before planning any modification.

Safety and Handling

• Regulatory status: For research use only (Product Data). Not for human or veterinary use.
• GHS classification / pictograms / H-statements (item-specific): Not specified for this item; refer to SDS for authoritative safety information.
• General laboratory precautions (good practice for peptides and small bioactive molecules):
  • Wear appropriate PPE: lab coat, gloves (nitrile), safety glasses or face shield.
  • Avoid inhalation of powders and contact with skin/eyes. Handle solids in a fume hood or containment to minimize dust/aerosol.
  • Prevent cross-contamination of bioassays; use dedicated tools for weighing and dissolution.
• Potential hazards (general): Peptides typically present low volatility. Sensitization is possible upon repeated exposure to bioactive peptides; avoid aerosol generation.
• First aid (general guidance; defer to SDS):
  • Inhalation: move to fresh air; seek medical attention if symptoms occur.
  • Skin/eye contact: rinse with water for several minutes; remove contaminated clothing; seek medical advice if irritation persists.
  • Ingestion: rinse mouth; do not induce vomiting; seek medical attention.
• Incompatibilities (general): Strong oxidizers may degrade amino-acid residues; elevated pH and high temperatures can promote hydrolysis/deamidation. Protect from moisture for solid materials.

Always consult the product-specific SDS before use for definitive hazard classification and response measures.

Solvent Selection

• Item-specific solubility: Not specified for this item; refer to CoA/Spec Sheet.

• General strategy for dissolving short peptides:

  • Start with water or buffer at the target pH. If insoluble, try a minimal amount of DMSO to form a concentrate, then dilute into aqueous media while monitoring for precipitation.
  • For acidic peptides (Asp/Glu-rich), adjust to slightly basic pH (7.5–8.5). For basic peptides (Lys/Arg/His-rich), adjust to slightly acidic pH (5.5–6.5) using acetate or phosphate buffers.
  • Use 0.1% TFA or dilute HCl in water for initial solubilization of strongly basic sequences, then neutralize to assay conditions.
  • For hydrophobic sequences, co-solvents like acetonitrile (MeCN) or isopropanol (≤20%) can aid dissolution before final dilution.

• Dielectric/polarity considerations (general): Aqueous buffers (high dielectric) stabilize ionic peptide forms; DMSO/MeCN improve solvation of hydrophobic side chains but may affect biological assays—keep final organic ≤1–2% v/v when possible.

• Compatibility notes: Avoid strong oxidants and prolonged exposure to basic pH. Filter sterilize (0.22 μm) if sterility is required. Always verify solubility visually and by analytical methods (HPLC/UV) after preparation.

Storage and Reconstitution

• Storage conditions (Product Data): Room temperature for the supplied form. Protect from moisture and direct light. Avoid prolonged exposure to elevated humidity.

• Shipping (Product Data): Not specified for this item; refer to CoA/Spec Sheet.

• Reconstitution (general guidance for peptides):

  • Use sterile, high-purity water or buffer. If solubility is limited, dissolve first in a minimal volume of DMSO or dilute acid (e.g., 0.1% TFA), then dilute with buffer to the desired concentration.
  • Aim for gentle mixing; avoid vigorous vortexing that can cause foaming/adsorption losses.
  • If sterility is required, filter through a 0.22 μm membrane after dissolution.

• Storage after reconstitution (general):

  • Prepare single-use aliquots to avoid freeze–thaw. Store aqueous stocks at 2–8°C for short term (hours to a few days) and at −20 to −80°C for longer-term stability, as compatible with your assay.
  • Assess stability by periodic HPLC/LC-MS. Discard solutions showing precipitation or degradation.

For lot-specific solubility, pH limits, counterion form, and stability data, consult the CoA/Spec Sheet. Always follow your institution’s best practices for handling peptide solutions.

Structure and Identity

Thymocartin (SKU T1041399) is offered as a research-only small-molecule/peptidic compound in Aladdin Scientific’s screening library.

• Product identifiers (from Product Data)

  • CAS: 85466-18-8
  • PubChem CID: 3033954
  • InChIKey: 49440 (as provided)
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.

• Structural features (general/literature context)

  • The name “Thymocartin” is commonly associated with a short, thymus-derived peptide motif; however, the precise sequence/structure for this catalog item is not specified here. Consult the CoA for definitive structural representation.
  • If peptidic, expected functional groups would include amide bonds, terminal amino/carboxyl functionalities, and side-chain heteroatoms depending on sequence (general peptide chemistry).

• 2D structure (descriptive, general to peptides)

  • Typical peptidic structures display a backbone of alternating carbonyl (C=O) and amide N–H units forming a linear oligomer, optionally bearing ionizable side chains. Stereocenters, when present, arise from L-α-amino acid residues. Precise stereochemistry, sequence, and protecting groups for this item are not specified; please refer to the CoA/Spec Sheet for the definitive structure.

Synthetic Utility

Thymocartin is a finished small-molecule/peptidic research compound and is not typically employed as a general synthetic reagent.

• When derivatization is desired (general peptide chemistry):

  • N-terminal or lysine ε-amines can be acylated (e.g., NHS-esters) or labeled with fluorophores/biotin; cysteine thiols (if present) can be targeted via maleimide or haloacetyl chemistry.
  • Click-chemistry handles (azide/alkyne) may be introduced for conjugation, but sequence-specific reactivity and protecting-group strategies are required.
  • Solid-phase re-synthesis allows incorporation of isotopic labels or noncanonical residues for mechanistic studies.

• Analytical method development: The compound can serve as a test article for LC-MS/MS optimization (ionization mode, collision energies, retention tuning), provided identity/purity are documented on the lot CoA.

If your application requires a functional handle (e.g., fluorescent tag, affinity tag), consider requesting a custom synthesis or referencing sequence details (not provided here) to ensure site-selective modification.

Target Specificity

Not applicable. This product is not an antibody or affinity reagent, and no target specificity data are provided in the Product Data. If used as a probe in binding assays, determine target engagement empirically and consult primary literature relevant to your experimental model.